Nitin Jain
Experienced in Peritonitis

Dr. Nitin Jain

Radiology
Henry Ford St. John Hospital
22101 Moross Rd, 
Detroit, MI 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Peritonitis
Henry Ford St. John Hospital
22101 Moross Rd, 
Detroit, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nitin Jain is a Radiologist in Detroit, Michigan. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Peritonitis. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Small Lymphocytic Lymphoma (SLL), Ascites, Bone Marrow Aspiration, and Endoscopy.

His clinical research consists of co-authoring 492 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Licenses
Diagnostic Radiology in MI
Hospital Affiliations
Henry Ford Health Warren Hospital
Henry Ford Health St John Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Henry Ford St. John Hospital
22101 Moross Rd, Detroit, MI 48236
Call: 313-343-4000
Other Locations
Henry Ford Warren Hospital
11800 E 12 Mile Rd, Warren, MI 48093
Call: 586-573-5000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Enrollment Status: Recruiting
Publish Date: August 14, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Atezolizumab, Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: December 12, 2025
Intervention Type: Biological
Study Drug: ADCT-602 Monoclonal Antibody
Study Phase: Phase 1/Phase 2
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Ibrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 2
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Terminated
Publish Date: June 08, 2025
Intervention Type: Drug, Biological, Other
Study Phase: Phase 2
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: MS-553
Study Phase: Phase 1/Phase 2
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Enrollment Status: Withdrawn
Publish Date: February 28, 2025
Intervention Type: Drug, Biological
Study Drugs: Ibrutinib, Ipilimumab, Nivolumab
Study Phase: Phase 1
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Nivolumab
Study Phase: Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Biological, Drug
Study Drugs: Bosutinib, Inotuzumab, Ozogamicin
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Terminated
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

492 Total Publications

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Journal: Leukemia
Published: December 10, 2025
View All 492 Publications
Similar Doctors
Monzer A. Chehab
Advanced in Peritonitis
Dr. Monzer A. Chehab
Interventional Radiology | Radiology
Advanced in Peritonitis
Dr. Monzer A. Chehab
Interventional Radiology | Radiology

Drs Harris Birkhill Wang Songe And Associates PC

840 Oakwood Boulevard, 
Dearborn, MI 
 (19.0 miles away)
313-359-7600
Experience:
15+ years
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Monzer Chehab is a Radiologist and an Interventional Radiologist in Dearborn, Michigan. Dr. Chehab has been practicing medicine for over 15 years and is rated as an Advanced provider by MediFind in the treatment of Peritonitis. His top areas of expertise are Lung Nodules, Ascites, Lung Cancer, Bone Marrow Aspiration, and Liver Embolization. Dr. Chehab is currently accepting new patients.

Advanced in Peritonitis
Dr. Pierre Zayat
Radiology
Advanced in Peritonitis
Dr. Pierre Zayat
Radiology

St. John Hospital And Medical Center

22101 Moross Rd, 
Detroit, MI 
 (7.5 miles away)
313-881-0411
Languages Spoken:
English
See accepted insurances

Pierre Zayat is a Radiologist in Detroit, Michigan. Dr. Zayat is rated as a Distinguished provider by MediFind in the treatment of Peritonitis. His top areas of expertise are Ascites, Gas Bloat Syndrome, Pleurisy, Endoscopy, and Bone Marrow Aspiration.

Terrence Metz
Advanced in Peritonitis
Dr. Terrence Metz
Pediatric Radiology | Radiology | Interventional Radiology
Advanced in Peritonitis
Dr. Terrence Metz
Pediatric Radiology | Radiology | Interventional Radiology

Corewell Health William Beaumont University Hospital Interventional Radiology Clinic

3601 W 13 Mile Rd, 
Royal Oak, MI 
 (9.6 miles away)
248-898-7456
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Terrence Metz is a Pediatric Radiologist and a Radiologist in Royal Oak, Michigan. Dr. Metz has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Peritonitis. His top areas of expertise are Ascites, Pleurisy, Thyroid Nodule, Congenital Athymia, and Splenectomy. Dr. Metz is currently accepting new patients.

VIEW MORE PERITONITIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
  • Elite
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Jain is
    Elite
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Small Lymphocytic Lymphoma (SLL)
    Dr. Jain is
    Elite
    . Learn about Small Lymphocytic Lymphoma (SLL).
    See more Small Lymphocytic Lymphoma (SLL) experts
  • Distinguished
  • Ascites
    Dr. Jain is
    Distinguished
    . Learn about Ascites.
    See more Ascites experts
  • Advanced
  • Bone Marrow Aspiration
    Dr. Jain is
    Advanced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Febrile Neutropenia
    Dr. Jain is
    Advanced
    . Learn about Febrile Neutropenia.
    See more Febrile Neutropenia experts
  • Hepatic Venoocclusive Disease with Immunodeficiency
    Dr. Jain is
    Advanced
    . Learn about Hepatic Venoocclusive Disease with Immunodeficiency.
    See more Hepatic Venoocclusive Disease with Immunodeficiency experts
  • Lymphofollicular Hyperplasia
    Dr. Jain is
    Advanced
    . Learn about Lymphofollicular Hyperplasia.
    See more Lymphofollicular Hyperplasia experts
  • Mikulicz Disease
    Dr. Jain is
    Advanced
    . Learn about Mikulicz Disease.
    See more Mikulicz Disease experts
  • Pleural Effusion
    Dr. Jain is
    Advanced
    . Learn about Pleural Effusion.
    See more Pleural Effusion experts
View All 8 Advanced Conditions
  • Experienced
  • Alcoholic Cirrhosis
    Dr. Jain is
    Experienced
    . Learn about Alcoholic Cirrhosis.
    See more Alcoholic Cirrhosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Jain is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Arthritis
    Dr. Jain is
    Experienced
    . Learn about Arthritis.
    See more Arthritis experts
  • Biliary Dyskinesia
    Dr. Jain is
    Experienced
    . Learn about Biliary Dyskinesia.
    See more Biliary Dyskinesia experts
  • Bronchogenic Cyst
    Dr. Jain is
    Experienced
    . Learn about Bronchogenic Cyst.
    See more Bronchogenic Cyst experts
  • Caffey Disease
    Dr. Jain is
    Experienced
    . Learn about Caffey Disease.
    See more Caffey Disease experts
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.